British National Lymphoma Investigation: Pilot studies of neoadjuvant chemotherapy in clinical stage Ia and IIa Hodgkin's disease

Clinical Oncology

Volumn 13, Issue 4, 2001, Pages 262-268

  Moody, A M ^a   Pratt, J ^a   Vaughan Hudson, G ^b   Smith, P ^b   Lamont, A ^c   Williams, M V ^a  

^a CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b MIDDLESEX HOSPITAL   (United Kingdom)

^c Southend Hospital   (United Kingdom)

Author keywords

Hodgkin's disease; Involved field radiotherapy; Neoadjuvant chemotherapy; Pulmonary toxicity

Indexed keywords

ALKYLATING AGENT; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISOLONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SCREENING; ESOPHAGITIS; FEBRILE NEUTROPENIA; FEMALE; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; ORGANIZATION; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENCE RISK; SIDE EFFECT; SURVIVAL RATE;

EID: 0034866440     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1053/clon.2001.9265     Document Type: Article

References (20)

1. Hopestone HF. The place of radiotherapy in the management of localised Hodgkin's disease. Clin Radiol 1981;32:519-22.
2. Haybittle JL, Hayhoe FGJ, Easterling MJ, et al. Review of the British National Lymphoma Investigation studies of Hodgkin's disease and development of a prognostic index. Lancet 1985;i:967-72.
3. Godspodarowicz MK, Sutcliffe SB, Bergsagel DE, et al. Radiation therapy in clinical Stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group. Eur J Cancer 1992;28A:1841-6.
4. Tubiana M, Henry-Amar M, Hayat M, et al. Long-term results of the EORTC randomised study of irradiation and vinblastine in clinical Stage I and II of Hodgkin's disease. Eur J Cancer 1979;15:645-57.
5. Linch DC, Vaughan Hudson B. The management of Hodgkin's and non-Hodgkin's lymphoma. In: Hoffbrand AV, editor. Recent advances in clinical haematology, 5. 1988:221-42.
6. Bates NP, Williams MV, Bessell EM, et al. Efficacy and toxicity of vinblastine, bleomycin and methotrexate with involved-field radiotherapy in clinical Stage IA and IIA Hodgkin's disease. A British National Lymphoma Investigation pilot study. J Clin Oncol 1994;12:288-96.
7. Swerdlow AJ, Douglas AJ, Vaughan Hudson G, et al. Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation. BMJ 1992;304:1137-43.
8. Swerdlow AJ, Barber JA, Horwich A, et al. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer 1997;75:116-23.
9. Report of a Working Party of the Joint Council for Clinical Oncology. Management of gonadal toxicity resulting from the treatment of adult cancer. London: Royal College of Physicians, 1998.
10. Boivin J-F, Hutchinson GB, Lubin JH, et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992;69:1241-7.
11. Dubray B, Henry-Amar M, Meerwaldt JH, et al. Radiation-induced lung damage after thoracic irradiation for Hodgkin's disease: the role of fractionation. Radiother Oncol 1995;36:211-7.
12. Horning SJ, Hoppe RT, Hancock SL, et al. Vinblastine, bleomycin and methotrexate: an effective adjuvant in favourable Hodgkin's disease. J Clin Oncol 1988;6:1822-31.
13. Gobbi PG, Pieresca C, Frassoldati A, et al. Vinblastine, bleomycin and methotrexate chemotherapy plus extended-field radiotherapy in early, favourably presenting, clinically staged Hodgkin's patients: the Gruppo Italiane per lo Studio dei Linformi experience. J Clin Oncol 1996;14:527-33.
14. Shapiro CL, Yeap BY, Godleski J, et al. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma. Comparative results with three different treatment regimens. Cancer 1991;68:699-705.
15. Gillespie AM, Lorigan PC, Radstone CR, et al. Pulmonary function in patients with trophoblastic disease treated with low-dose methotrexate. Br J Cancer 1997;76:1382-6.
16. Theuws JCM, Muller SH, Seppenwoolde Y, et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: a follow-up study. J Clin Oncol 1999;17:3091-100.
17. Radford JA, Cowan RA, Ryder WDJ, et al. Four weeks of neo-adjuvant chemotherapy significantly reduces the progression rate in patients treated with limited field radiotherapy for clinical I/IIA Hodgkin's disease. Results of a randomised pilot study [abstract]. Ann Oncol 1996;7(Suppl3):21.
18. Carde P, Noordijk EM, Hasenbeck A, et al. Superiority of EBVP chemotherapy in combination with involved field irradiation of (EBVP/IF) over subtotal nodal irradiation (STNI) in favourable clinical stage (CS) I-II Hodgkin's disease. The EORTC-GPMC H7F randomised trial [abstract]. Proc ASCO 1997;16:13.
19. Noordijk EM, Carde P, Mandard AM, et al. Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie. Ann Oncol 1994;5(Suppl 2):107-12.
20. Sieber M, Rüffer V, Jostin A, et al. Treatment of Hodgkin's disease. Current strategies of the German Lymphoma Study Group. Ann Oncol 1999;10(Suppl 6):523-9.